Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Doctoral Award - Frederick Banting and Charles Best Canada Graduate Scholarships

McGill University

$105,000.00

Physiological Mechanisms of Dyspnea Relief and Improved Exercise Tolerance after Treatment with Oral Morphine in Patients with advanced Chronic Obstructive Pulmonary Disease

EF 2014-15

Résumé
Breathlessness is the most common symptom in COPD patients and is considered to be the primary limiting factor in activities of daily living. To date, the majority of available therapies for COPD patients, such as bronchodilators and corticosteroids, target the underlying components of the disease itself, with the secondary aim of relieving breathlessness and improving exercise capacity and quality of life. Although this approach has been proven to be effective, many COPD patients receiving optimal medical treatments from their health care provider remain symptomatic, particularly those in the later stages of the disease. Under these circumstances, pain-relieving (opioid) medications, such as morphine, may be used to alleviate breathlessness and improve exercise tolerance. The objectives of this study are to determine whether or not the oral administration of the pain relieving medication, morphine sulfate, can (1) reduce breathlessness and (2) increase exercise tolerance in patients with severe COPD, and if so (3) determine its mechanisms of action in the body. This will be the first study to evaluate the effects of single-dose administration of oral morphine on lung function and the electrical activity of the largest breathing muscle (the diaphragm; using a specially designed catheter) in combination with detailed assessments of breathlessness and exercise capacity in symptomatic patients with severe COPD on optimal medical therapy. The proposed study aims to (1) accelerate respiratory research in Canada by providing detailed physiological evidence for the use of oral morphine in the treatment of breathlessness in patients with COPD, and (2) augment opportunities for respiratory research by elucidating the mechanisms of action of oral morphine on the organ system and whole body level, ultimately (3) providing health care professionals with additional means of improving health related quality of life for patients with lung disease.
Programme
Doctoral Award - Frederick Banting and Charles Best Canada Graduate Scholarships
Bénéficiaire
Emplacement
Quebec, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
327773
Name
Abdallah Sara
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Circulatory and Respiratory Health
Theme2
Clinical
Prcname2
Doctoral Research Awards - A
Projecttitle
Physiological Mechanisms of Dyspnea Relief and Improved Exercise Tolerance after Treatment with Oral Morphine in Patients with advanced Chronic Obstructive Pulmonary Disease
Programtype2
Studentship Programs
Orgnameinp2
McGill University
Cihramount2
$105,000
Cihrequipment2
$0
Programname2
Doctoral Award - Frederick Banting and Charles Best Canada Graduate Scholarships
Keyworddelim
Breathlessness; Copd; Dyspnea; Exercise; Lung; Morphine; Opioid
Abstract
Breathlessness is the most common symptom in COPD patients and is considered to be the primary limiting factor in activities of daily living. To date, the majority of available therapies for COPD patients, such as bronchodilators and corticosteroids, target the underlying components of the disease itself, with the secondary aim of relieving breathlessness and improving exercise capacity and quality of life. Although this approach has been proven to be effective, many COPD patients receiving optimal medical treatments from their health care provider remain symptomatic, particularly those in the later stages of the disease. Under these circumstances, pain-relieving (opioid) medications, such as morphine, may be used to alleviate breathlessness and improve exercise tolerance. The objectives of this study are to determine whether or not the oral administration of the pain relieving medication, morphine sulfate, can (1) reduce breathlessness and (2) increase exercise tolerance in patients with severe COPD, and if so (3) determine its mechanisms of action in the body. This will be the first study to evaluate the effects of single-dose administration of oral morphine on lung function and the electrical activity of the largest breathing muscle (the diaphragm; using a specially designed catheter) in combination with detailed assessments of breathlessness and exercise capacity in symptomatic patients with severe COPD on optimal medical therapy. The proposed study aims to (1) accelerate respiratory research in Canada by providing detailed physiological evidence for the use of oral morphine in the treatment of breathlessness in patients with COPD, and (2) augment opportunities for respiratory research by elucidating the mechanisms of action of oral morphine on the organ system and whole body level, ultimately (3) providing health care professionals with additional means of improving health related quality of life for patients with lung disease.
Competitiondate
201410
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Abdallah, Sara
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $105,000~ $0~